

SAFETY DATA SHEET

1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

1.1 Product identifier

Product name FELIMAZOLE (1.25MG, 2.5MG AND 5MG) COATED TABLET

Synonyms FELIMAZOLE

1.2 Uses and uses advised against

Uses CAT TREATMENT ● VETERINARY APPLICATIONS ● VETERINARY USE

For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy. For the long term treatment of

feline hyperthyroidism.

Uses advised against Do not use in cats suffering from systemic disease such as primary liver disease or diabetes mellitus. Do not

Page 1 of 7

use in cats showing signs of autoimmune disease. Do not use in animals with disorders of white blood cells, such as neutropenia and lymphopenia. Do not use in animals with platelet disorders and coagulopathies (particularly thrombocytopenia). Do not use in cats with hypersensitivity to thiamazole or the excipient,

polyethylene glycol.

Do not use in pregnant or lactating females.

1.3 Details of the supplier of the product

Supplier name DECHRA VETERINARY PRODUCTS (AUSTRALIA) PTY LTD

Address 2 Cal Close, Somersby, NSW, 2250, AUSTRALIA

Telephone 1300 015 825; (02) 4372 1661

 Fax
 (02) 4372 1668

 Email
 info.au@dechra.com

 Website
 http://www.dechra.com.au/

1.4 Emergency telephone numbers

Emergency 13 11 26 (Poisons Information Centre)

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

CLASSIFIED AS HAZARDOUS ACCORDING TO SAFE WORK AUSTRALIA CRITERIA

Physical Hazards

Not classified as a Physical Hazard

Health Hazards

Acute Toxicity: Oral: Category 4 Skin Sensitisation: Category 1

Specific Target Organ Toxicity (Single Exposure): Category 3 (Respiratory Irritation)

Germ Cell Mutagenicity: Category 2 Toxic to Reproduction: Category 2

Environmental Hazards

Not classified as an Environmental Hazard

2.2 GHS Label elements

Signal word WARNING



SDS Date: 19 Apr 2021

Pictograms





Hazard statements

H302 Harmful if swallowed.

May cause an allergic skin reaction. H317 H335 May cause respiratory irritation. H341 Suspected of causing genetic defects.

H361 Suspected of damaging fertility or the unborn child.

Prevention statements

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P261 Avoid breathing dust/fume/gas/mist/vapours/spray.

P264 Wash thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P271 Use only outdoors or in a well-ventilated area.

P272 Contaminated work clothing should not be allowed out of the workplace. P280 Wear protective gloves/protective clothing/eye protection/face protection.

Response statements

P302 + P352 IF ON SKIN: Wash with plenty of soap and water.

P304 + P340 IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing.

P308 + P313 IF exposed or concerned: Get medical advice/ attention. P321 Specific treatment is advised - see first aid instructions.

P330 Rinse mouth.

P363 Wash contaminated clothing before reuse.

Storage statements

P403 + P233 Store in a well-ventilated place. Keep container tightly closed.

P405 Store locked up.

Disposal statements

P501 Dispose of contents/container in accordance with relevant regulations.

2.3 Other hazards

No information provided.

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances / Mixtures

Ingredient	CAS Number	EC Number	Content
1-METHYL-3H-IMIDAZOLE-2-THIONE	60-56-0	200-482-4	2.5 to 5%
NON HAZARDOUS INGREDIENTS	Not Available	Not Available	Remainder

4. FIRST AID MEASURES

4.1 Description of first aid measures

If in eyes, hold eyelids apart and flush continuously with running water. Continue flushing until advised to Eye

stop by a Poisons Information Centre, a doctor, or for at least 15 minutes.

Inhalation If inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Also rest and keep

warm.

Skin If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.

Continue flushing with water until advised to stop by a Poisons Information Centre or a doctor.

For advice, contact a Poisons Information Centre on 13 11 26 (Australia Wide) or a doctor (at once). If Ingestion

swallowed, do not induce vomiting.

First aid facilities Eye wash facilities and a hand wash basin are recommended.

4.2 Most important symptoms and effects, both acute and delayed

See Section 11 for more detailed information on health effects and symptoms.



4.3 Immediate medical attention and special treatment needed

Treat symptomatically.

5. FIRE FIGHTING MEASURES

5.1 Extinguishing media

Use an extinguishing agent suitable for the surrounding fire.

5.2 Special hazards arising from the substance or mixture

Non flammable. May evolve carbon oxides, sulphur oxides and hydrocarbons when heated to decomposition.

5.3 Advice for firefighters

Treat as per requirements for surrounding fires. Evacuate area and contact emergency services. Remain upwind and notify those downwind of hazard. Wear full protective equipment including Self Contained Breathing Apparatus (SCBA) when combating fire. Use waterfog to cool intact containers and nearby storage areas.

5.4 Hazchem code

None allocated.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Wear Personal Protective Equipment (PPE) as detailed in section 8 of the SDS.

6.2 Environmental precautions

Prevent product from entering drains and waterways.

6.3 Methods of cleaning up

If spilt, collect and reuse where possible.

6.4 Reference to other sections

See Sections 8 and 13 for exposure controls and disposal.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Before use carefully read the product label. Use of safe work practices are recommended to avoid eye or skin contact and inhalation. Observe good personal hygiene, including washing hands before eating. Prohibit eating, drinking and smoking in contaminated areas.

7.2 Conditions for safe storage, including any incompatibilities

Store in a cool, dry, well marked area, removed from foodstuffs and other drugs. Storage areas and containers should be clearly marked for drug holding, protected from light, freezing or physical damage and tightly sealed when not in use. Keep out of reach of children. Store below 25°C. Keep the blister strips in the carton.

Page 3 of 7

7.3 Specific end uses

No information provided.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

8.1 Control parameters

Exposure standards

No exposure standards have been entered for this product.

Biological limits

No biological limit values have been entered for this product.

8.2 Exposure controls

Engineering controls Avoid inhalation. Use in well ventilated areas.

ChemAlert.

SDS Date: 19 Apr 2021

PPE

Eye / Face Not required under normal conditions of use.

Hands Individuals with sensitive skin should consider wearing latex gloves.

Body Not required under normal conditions of use. **Respiratory** Not required under normal conditions of use.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance RED SOLID

Odour CHARACTERISTIC ODOUR

Flammability NON FLAMMABLE Flash point NOT RELEVANT

Boiling point 280°C

Melting point 146°C to 148°C **Evaporation rate NOT AVAILABLE** pН **NOT AVAILABLE** Vapour density **NOT AVAILABLE** Relative density **NOT AVAILABLE** Solubility (water) **NOT AVAILABLE** Vapour pressure **NOT AVAILABLE** Upper explosion limit NOT RELEVANT Lower explosion limit NOT RELEVANT Partition coefficient NOT AVAILABLE **Autoignition temperature** NOT AVAILABLE **Decomposition temperature** NOT AVAILABLE **Viscosity** NOT AVAILABLE **Explosive properties NOT AVAILABLE Oxidising properties NOT AVAILABLE Odour threshold NOT AVAILABLE**

10. STABILITY AND REACTIVITY

10.1 Reactivity

Carefully review all information provided in sections 10.2 to 10.6.

10.2 Chemical stability

Stable under recommended conditions of storage.

10.3 Possibility of hazardous reactions

Polymerization will not occur.

10.4 Conditions to avoid

Avoid contact with incompatible substances.

10.5 Incompatible materials

Compatible with most commonly used materials.

10.6 Hazardous decomposition products

May evolve carbon oxides and hydrocarbons when heated to decomposition.

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity

Harmful if swallowed. This product is used in veterinary applications. Use safe work practices to avoid eye contact, prolonged skin contact and ingestion. Refer to medical doctor/specialist for advice regarding

adverse side effects.



SDS Date: 19 Apr 2021

Information available for the ingredients:

Ingredient	Oral LD50	Dermal LD50	Inhalation LC50
1-METHYL-3H-IMIDAZOLE-2-THIONE	2250 mg/kg (rat)		

Skin Contact may result in irritation, redness and rash.

Eye Contact may result in irritation, lacrimation, pain, redness and conjunctivitis.

Sensitisation May cause an allergic skin reaction. May cause allergy or asthma symptoms or breathing difficulties if

inhaled.

Mutagenicity Suspected of causing genetic defects.

Carcinogenicity Not classified as a carcinogen.

Reproductive Suspected of damaging fertility or the unborn child.

STOT - single exposure

Over exposure may result in irritation of the nose and throat, with coughing.

STOT - repeated

exposure

Not classified as causing organ damage from repeated exposure.

Aspiration Not classified as causing aspiration.

12. ECOLOGICAL INFORMATION

12.1 Toxicity

No information provided.

12.2 Persistence and degradability

No information provided.

12.3 Bioaccumulative potential

No information provided.

12.4 Mobility in soil

No information provided.

12.5 Other adverse effects

No information provided.

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste disposal For small quantities, collect and place in sealable containers. Dispose of, as with other clinical waste, by high

temperature incineration (recommended > 1100°C). Burial to landfill may be acceptable, but only at an

approved and licensed waste disposal site.

Legislation Dispose of in accordance with relevant local legislation.

14. TRANSPORT INFORMATION

NOT CLASSIFIED AS A DANGEROUS GOOD BY THE CRITERIA OF THE ADG CODE, IMDG OR IATA

	LAND TRANSPORT (ADG)	SEA TRANSPORT (IMDG / IMO)	AIR TRANSPORT (IATA / ICAO)
14.1 UN Number	None allocated.	None allocated.	None allocated.
14.2 Proper Shipping Name	None allocated.	None allocated.	None allocated.
14.3 Transport hazard class	None allocated.	None allocated.	None allocated.
14.4 Packing Group	None allocated.	None allocated.	None allocated.

14.5 Environmental hazards

No information provided.

14.6 Special precautions for user



SDS Date: 19 Apr 2021 Revision No: 1

Page 5 of 7

Hazchem code None allocated.

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Poison schedule Classified as a Schedule 4 (S4) Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP).

APVMA Numbers 63927 (2.5mg) • 63928 (5mg) • 88436 (1.25mg)

Classifications Safework Australia criteria is based on the Globally Harmonised System (GHS) of Classification and

Labelling of Chemicals.

Inventory listings AUSTRALIA: AllC (Australian Inventory of Industrial Chemicals)

All components are listed on AIIC, or are exempt.

EUROPE: EINECS (European Inventory of Existing Chemical Substances)

All components are listed on EINECS, or are exempt.

16. OTHER INFORMATION

Additional information

WORKPLACE CONTROLS AND PRACTICES: Unless a less toxic chemical can be substituted for a hazardous substance, ENGINEERING CONTROLS are the most effective way of reducing exposure. The best protection is to enclose operations and/or provide local exhaust ventilation at the site of chemical release. Isolating operations can also reduce exposure. Using respirators or protective equipment is less effective than the controls mentioned above, but is sometimes necessary.

PERSONAL PROTECTIVE EQUIPMENT GUIDELINES:

The recommendation for protective equipment contained within this report is provided as a guide only. Factors such as form of product, method of application, working environment, quantity used, product concentration and the availability of engineering controls should be considered before final selection of personal protective equipment is made.

HEALTH EFFECTS FROM EXPOSURE:

It should be noted that the effects from exposure to this product will depend on several factors including: form of product; frequency and duration of use; quantity used; effectiveness of control measures; protective equipment used and method of application. Given that it is impractical to prepare a report which would encompass all possible scenarios, it is anticipated that users will assess the risks and apply control methods where appropriate.

Abbroviations	ACGIH	American Conference of Covernmental Industrial Hygionists
Abbreviations	ACGIR	American Conference of Governmental Industrial Hygienists

CAS # Chemical Abstract Service number - used to uniquely identify chemical compounds

CNS Central Nervous System

EC No. EC No - European Community Number

EMS Emergency Schedules (Emergency Procedures for Ships Carrying Dangerous

Goods)

GHS Globally Harmonized System

GTEPG Group Text Emergency Procedure Guide IARC International Agency for Research on Cancer

LC50 Lethal Concentration, 50% / Median Lethal Concentration

LD50 Lethal Dose, 50% / Median Lethal Dose

mg/m³ Milligrams per Cubic Metre
OEL Occupational Exposure Limit

pH relates to hydrogen ion concentration using a scale of 0 (high acidic) to 14 (highly

alkaline).

ppm Parts Per Million

STEL Short-Term Exposure Limit

STOT-RE Specific target organ toxicity (repeated exposure)
STOT-SE Specific target organ toxicity (single exposure)

Page 6 of 7

SUSMP Standard for the Uniform Scheduling of Medicines and Poisons

SWA Safe Work Australia
TLV Threshold Limit Value
TWA Time Weighted Average

ChemAlert.

SDS Date: 19 Apr 2021

Report status

This document has been compiled by RMT on behalf of the manufacturer, importer or supplier of the product and serves as their Safety Data Sheet ('SDS').

It is based on information concerning the product which has been provided to RMT by the manufacturer, importer or supplier or obtained from third party sources and is believed to represent the current state of knowledge as to the appropriate safety and handling precautions for the product at the time of issue. Further clarification regarding any aspect of the product should be obtained directly from the manufacturer, importer or supplier.

While RMT has taken all due care to include accurate and up-to-date information in this SDS, it does not provide any warranty as to accuracy or completeness. As far as lawfully possible, RMT accepts no liability for any loss, injury or damage (including consequential loss) which may be suffered or incurred by any person as a consequence of their reliance on the information contained in this SDS.

Prepared by

Risk Management Technologies 5 Ventnor Ave, West Perth Western Australia 6005 Phone: +61 8 9322 1711

Fax: +61 8 9322 1794 Email: info@rmt.com.au Web: www.rmtglobal.com

[End of SDS]



SDS Date: 19 Apr 2021